CURX · Curanex Pharmaceuticals Inc Common Stock

This 8-K filing conveys high-materiality operational and strategic developments for Curanex Pharmaceuticals. The completion of two critical IND-enabling milestones — GMP pilot manufacturing and a clean dose-range finding toxicology study — directly de-risks the planned Q4 2026 IND submission for Phyto-N in ulcerative colitis, bringing the asset closer to human clinical testing. The absence of treatment-related adverse findings at the maximum feasible dose in both rats and dogs is a positive signal for tolerability and bolsters confidence in advancing to formal GLP toxicology studies. The pipeline expansion into cancer cachexia is strategically significant: it targets a serious, underserved condition with no FDA-approved therapies and leverages biological overlap (inflammation, metabolic dysfunction) with the company’s existing focus, potentially broadening long-term value creation. While the $4.0 million cash balance is modest, management explicitly affirms it is sufficient to fund near-term IND-enabling work — a key liquidity checkpoint for preclinical biotechs. Importantly, all disclosures are made under Item 7.01 and Exhibit 99.1, meaning they are not subject to Section 18 liability or incorporation-by-reference rules, limiting legal exposure but also signaling non-core regulatory filing status. Investors should monitor progress against the Q4 2026 IND timeline and future updates on GLP study execution and cancer cachexia development planning.